RevitalVision

Company Overview

Snapshot

Founded in December 2019 by Yair (Gottlieb) Yahav, RevitalVision operates with 11–50 employees. The company has raised $3.7M across three funding rounds. In January 2026, RevitalVision published positive clinical data for its digital therapeutic treatment for infantile Nystagmus.

Business overview

RevitalVision is a SaaS-based digital health startup focused on vision improvement within the ophthalmic marketplace. The company utilizes non-invasive technology to enhance eyesight neurologically, addressing the needs of individuals whose vision impairments are not met by traditional treatments. Its core technology is based on brain science and proprietary algorithms, clinically validated for various eye diseases and vision impairments. RevitalVision serves eye care specialists and eye surgery clinics, providing tools to improve patient vision beyond optical correction and offering solutions for post-surgery neuro-adaptation challenges.

Strategic signal

In January 2026, RevitalVision announced the publication of positive clinical data for its digital therapeutic treatment for infantile Nystagmus. This development is significant as it demonstrates the efficacy and safety of their technology for a specific, challenging vision disorder, validating the company's scientific approach and expanding the potential applications of its platform. For investors, this signals continued clinical progress and potential for broader market adoption within the digital therapeutics space.

Company Intelligence Q&A

What is RevitalVision's core technology?

RevitalVision utilizes brain science and proprietary algorithm-based technology to neurologically enhance eyesight. This non-invasive approach is designed to improve vision performance for individuals with various eye diseases and vision impairments.

What significant clinical milestone did RevitalVision achieve in January 2026?

In January 2026, RevitalVision announced the publication of positive clinical data for its digital therapeutic treatment for infantile Nystagmus, demonstrating its efficacy and safety.

What was the outcome of RevitalVision's new clinical trial announced in April 2024?

In April 2024, RevitalVision announced the successful outcome of a new clinical trial, further validating its vision technology.

Which vision impairment does RevitalVision's technology address, and what regulatory approval does it hold?

RevitalVision's technology is FDA-cleared for children older than 9 and adults with amblyopia (lazy eye). It has also received two new unique reimbursement codes from the American Medical Association for amblyopia treatment.

What was a key strategic development for RevitalVision in March 2021?

In March 2021, RevitalVision expanded its vision technology into the U.S. and European markets, indicating a strategic move towards international growth.